Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Support Care Cancer ; 27(11): 4083-4090, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30778756

RESUMEN

Constipation, one of the adverse effects of opioid therapy with a major impact on quality of life, is still an unmet need for cancer patients, particularly those with an advanced and progressive disease, and for non-cancer patients chronically treated with opioids. The awareness of this condition is poor among healthcare providers, despite the recent publication of guidelines and consensus conferences. An early multidisciplinary approach of opioid-induced bowel dysfunction (OIBD), based on available therapies of proven effectiveness, could support clinicians in managing this condition, thus increasing patients' adherence to pain therapy. Several Italian experts involved in the management of patients suffering from pain (anaesthesia pain therapy, oncology, haematology, palliative care, gastroenterology) joined in a Board in order to draw up an expert opinion on OIBD. The most frequent and still unsolved issues in this field were examined, including a more comprehensive definition of OIBD, the benefits of early intervention to prevent its occurrence and the most appropriate use of peripherally acting mu-opioid receptor antagonists (PAMORAs). The use of the recently introduced PAMORA naloxegol was analysed, in light of the current literature. The Board proposed a solution for each open issue in the form of recommendations, integrated with the contribution of representatives from different disciplines and often accompanied by procedural algorithms immediately usable and applicable in daily clinical practice. Safety and quality of life of the patient suffering from pain and from the adverse effects of pain therapies have been the mainstays of this expert opinion, in cooperation with general practitioners and caregivers.


Asunto(s)
Analgésicos Opioides/efectos adversos , Estreñimiento/inducido químicamente , Enfermedades Gastrointestinales/inducido químicamente , Dolor/tratamiento farmacológico , Calidad de Vida/psicología , Humanos
2.
J Clin Pharm Ther ; 44(3): 397-399, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30636175

RESUMEN

WHAT IS KNOWN AND OBJECTIVE: The exponential increase in chronic opioid consumers resulted in more challenges regarding post-operative pain management. Considering the usual hyperalgesic response to pain and the increased opioid-tolerance, a multidrug approach should be desirable. CASE DESCRIPTION: We described the strategy in pain management of a patient receiving methadone maintenance treatment, who underwent surgery associated with moderate post-operative pain. The combination of balanced general anaesthesia and intraoperative continuous low-dose infusion of ketamine assured an appropriate control of post-operative pain without increasing opioid consumption. Besides, it was not associated with psychomimetic effects. WHAT IS NEW AND CONCLUSION: Ketamine can effectively reduce opioid requirements in chronic opioid users on methadone maintenance therapy and should therefore be considered promptly as part of a multimodal perioperative analgesia management in this category of patients.


Asunto(s)
Heroína/efectos adversos , Hiperalgesia/prevención & control , Metadona/uso terapéutico , Trastornos Relacionados con Opioides/complicaciones , Analgésicos Opioides/uso terapéutico , Humanos , Ketamina/uso terapéutico , Masculino , Persona de Mediana Edad , Manejo del Dolor/métodos , Dolor Postoperatorio/tratamiento farmacológico , Atención Perioperativa , Periodo Posoperatorio
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA